- $892.15m
- $1.18bn
- $863.50m
- 35
- 73
- 45
- 49
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.71 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.12 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -11.18% | ||
Return on Equity | -18% | ||
Operating Margin | -24.75% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 901.93 | 1,435.41 | 1,774.72 | 1,004.2 | 863.5 | 717.66 | 756.81 | -2.7% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Directors
- Phillip Frost CHM (84)
- Jane Hsiao VCH (74)
- Adam Logal CFO (43)
- Jon Cohen CEX (67)
- Charles Bishop CEX (69)
- Tony Cruz CEX (67)
- Geoff Monk CEX (65)
- Katherine Stueland CEX (45)
- Steven Rubin EVP (61)
- Richard Krasno IND (79)
- Prem Lachman IND (60)
- Roger Medel IND (74)
- John Paganelli IND (86)
- Richard Pfenniger IND (65)
- Alice Yu IND (77)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 18th, 1991
- Public Since
- November 2nd, 1995
- No. of Shareholders
- 368
- No. of Employees
- 3,930
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 696,991,677
- Address
- 4400 Biscayne Blvd., MIAMI, 33137
- Web
- https://www.opko.com/
- Phone
- +1 3055754181
- Contact
- Yvonne Briggs
- Auditors
- Ernst & Young LLP
Upcoming Events for OPK
Q2 2024 OPKO Health Inc Earnings Release
Q3 2024 OPKO Health Inc Earnings Release
Similar to OPK
Acadia Healthcare
NASDAQ Global Select Market
Accolade
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
FAQ
As of Today at 19:16 UTC, shares in OPKO Health are trading at $1.28. This share price information is delayed by 15 minutes.
Shares in OPKO Health last closed at $1.28 and the price had moved by -28.09% over the past 365 days. In terms of relative price strength the OPKO Health share price has underperformed the S&P500 Index by -43.22% over the past year.
The overall consensus recommendation for OPKO Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
OPKO Health does not currently pay a dividend.
OPKO Health does not currently pay a dividend.
OPKO Health does not currently pay a dividend.
To buy shares in OPKO Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.28, shares in OPKO Health had a market capitalisation of $892.15m.
Here are the trading details for OPKO Health:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OPK
Based on an overall assessment of its quality, value and momentum OPKO Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in OPKO Health is $4.25. That is 232.03% above the last closing price of $1.28.
Analysts covering OPKO Health currently have a consensus Earnings Per Share (EPS) forecast of -$0.37 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OPKO Health. Over the past six months, its share price has underperformed the S&P500 Index by -14.19%.
As of the last closing price of $1.28, shares in OPKO Health were trading -5.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The OPKO Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
OPKO Health's management team is headed by:
- Phillip Frost - CHM
- Jane Hsiao - VCH
- Adam Logal - CFO
- Jon Cohen - CEX
- Charles Bishop - CEX
- Tony Cruz - CEX
- Geoff Monk - CEX
- Katherine Stueland - CEX
- Steven Rubin - EVP
- Richard Krasno - IND
- Prem Lachman - IND
- Roger Medel - IND
- John Paganelli - IND
- Richard Pfenniger - IND
- Alice Yu - IND